Current Report Filing (8-k)
July 30 2019 - 7:48AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
July
30, 2019
|
MERIDIAN BIOSCIENCE, INC.
|
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
Ohio
|
|
0-14902
|
|
31-0888197
|
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
3471 River Hills Drive
Cincinnati, Ohio
|
|
45244
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code
(513)
271-3700
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities
|
registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, no par value
|
|
VIVO
|
|
NASDAQ
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17CFR
§240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Item 2.02.
|
Results of Operations and Financial Condition.
|
On July 30, 2019, Meridian Bioscience, Inc. (
Meridian
or the
Company
) issued a press release announcing results for
the third fiscal quarter ended June 30, 2019. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated by reference herein.
Information in the press release contains forward-looking statements regarding future events and performance of the Company. All such forward-looking
statements are based largely on the Companys experience and perception of current conditions, trends, expected future developments and other factors, and on managements expectations, and are subject to risks and uncertainties that could
cause actual results to differ materially, including, but not limited to, those factors described in the release and in the Companys filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to
update or revise any financial or other projections or other forward-looking statements, whether because of new information, future events or otherwise.
The information in this Item 2.02 of this Form
8-K
and in the press release attached as Exhibit 99.1 is being
furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act
), or otherwise subject to the liabilities of that Section. The information in
this Item 2.02 of this Form
8-K
and Exhibit 99.1 shall not be incorporated by reference in any filing (whether made before or after the date hereof) or any other document under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing or document.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
MERIDIAN BIOSCIENCE, INC.
|
|
|
|
|
Date: July 30, 2019
|
|
|
|
|
|
By: /s/ Bryan T. Baldasare
|
|
|
|
|
|
|
Interim Chief Financial Officer and Chief Accounting Officer
|
|
|
|
|
|
|
(Principal Financial and Accounting Officer)
|
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Apr 2023 to Apr 2024